...
首页> 外文期刊>Applied Microbiology and Biotechnology >Monitoring of diguanylate cyclase activity and of cyclic-di-GMP biosynthesis by whole-cell assays suitable for high-throughput screening of biofilm inhibitors
【24h】

Monitoring of diguanylate cyclase activity and of cyclic-di-GMP biosynthesis by whole-cell assays suitable for high-throughput screening of biofilm inhibitors

机译:通过适用于高通量筛选生物膜抑制剂的全细胞测定法监测二鸟苷酸环化酶活性和环二GMP生物合成

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In Gram-negative bacteria, production of bis-(3′,5′)-cyclic diguanylic acid (c-di-GMP) by diguanylate cyclases (DGCs) is the main trigger for production of extracellular polysaccharides and for biofilm formation. Mutants affected in c-di-GMP biosynthesis are impaired in biofilm formation, thus making DGCs interesting targets for new antimicrobial agents with anti-biofilm activity. In this report, we describe a strategy for the screening for DGC inhibitors consisting of a combination of three microbiological assays. The primary assay utilizes an Escherichia coli strain overexpressing the adrA gene, encoding the DGC protein AdrA, and relies on detection of AdrA-dependent cellulose production as red colony phenotype on solid medium supplemented with the dye Congo red (CR). Presence of DGC inhibitors blocking AdrA activity would result in a white phenotype on CR medium. The CR assay can be performed in 96-well microtiter plates, making it suitable for high-throughput screenings. To confirm specific inhibition of c-di-GMP biosynthesis, chemical compounds positive in the CR assay are tested for their ability to inhibit biofilm formation and in a reporter gene assay which monitors expression of curli-encoding genes as a function of DGC activity. Screening of a chemical library using the described approach allowed us to identify sulfathiazole, an antimetabolite drug, as an inhibitor of c-di-GMP biosynthesis. Sulfathiazole probably affects c-di-GMP biosynthesis in an indirect fashion rather than by binding to DGCs; however, sulfathiazole represents the first example of drug able to affect biofilm formation by interfering with c-di-GMP metabolism.
机译:在革兰氏阴性细菌中,双鸟苷酸环化酶(DGC)产生双-(3',5')-环双鸟苷酸(c-di-GMP)是产生细胞外多糖和形成生物膜的主要诱因。受c-di-GMP生物合成影响的突变体在生物膜形成中受到损害,因此使DGC成为具有抗生物膜活性的新型抗菌剂的目标。在本报告中,我们描述了一种筛选DGC抑制剂的策略,该策略由三种微生物测定法的组合组成。初步分析利用了过表达adrA基因的大肠杆菌菌株,该菌株编码DGC蛋白AdrA,并依赖于AdrA依赖的纤维素产生的检测,其为补充有刚果红(CR)的固体培养基上的红色菌落表型。 DGC抑制剂阻断AdrA活性的存在会在CR培养基上产生白色表型。 CR分析可在96孔微量滴定板中进行,使其适用于高通量筛选。为了确认对c-di-GMP生物合成的特异性抑制作用,对CR分析呈阳性的化合物抑制生物膜形成的能力以及在报告基因分析中进行测试,该报告基因监测卷曲编码基因的表达与DGC活性的关系。使用所述方法筛选化学文库可以使我们鉴定出抗代谢药物磺胺噻唑,它是c-di-GMP生物合成的抑制剂。磺胺噻唑可能间接影响c-di-GMP的生物合成,而不是与DGC结合。然而,磺胺噻唑代表了能够通过干扰c-di-GMP代谢来影响生物膜形成的药物的第一个例子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号